- 1 Global, Regional, and National Burden of Pulmonary Arterial Hypertension, 1990-2021: a
- 2 Systematic Analysis of the Global Burden of Disease Study 2021
- 3

4 Authors

- 5 Yafang Deng^{a,b}, Xingbei Dong^a, Junyan Qian^a, Jiuliang Zhao^a, Dong Xu^a, Yanhong Wang^c,
- 6 Mengtao Li^a, Xiaofeng Zeng^a, Qian Wang^{a*}
- 7 ^{*}Correspondence: wangqian_pumch@126.com
- 8

9 Affiliations

- 10 a Department of Rheumatology and Clinical Immunology, Peking Union Medical College
- 11 Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College;
- 12 National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID),
- 13 Ministry of Science and Technology; State Key Laboratory of Complex Severe and Rare Diseases;
- 14 Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing
- 15 100730, China;
- 16 b School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing 100084, China;
- 17 c Department of Epidemiology and Bio-Statistics, Institute of Basic Medical Sciences, Chinese
- 18 Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing
- 19 100005, China.
- 20

21 Abstracts

- 22 Aims
- 23 Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular disease with high mortality
- 24 rates. This research aimed to examine the disease burden of PAH including prevalence, incidence,
- 25 mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021 across various age groups,
- 26 sexes, and Socio-demographic Index (SDI) levels, at global, regional and national levels.

27 Methods

- 28 Data was collected from the Global Burden of Diseases, Injuries, and Risk Factors study (GBD)
- 29 2021, which established models to estimate the burden of PAH for 204 countries and territories
- 30 from 1990 to 2021. Age-standardized rates for PAH prevalence, incidence, mortality, and DALYs
- 31 were calculated. Joinpoint regression was used to assess temporal trends. The correlation between
- 32 disease burden and socioeconomic development was analyzed.

33 Results

- 34 In 2021, the global age-standardized prevalence and incidence rates were 2.28 and 0.52 per
- 35 100,000 population, respectively. From 1990 to 2021, the age-standardized mortality rate
- 36 decreased from 0.35 to 0.27 per 100,000, with an average annual trend of -0.82%. The

Corresponding Author

Dr. Qian Wang, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, No. 1, Shuaifuyuan, Wangfujing Ave, Dongcheng District, Beijing 100730, China

E-Mail: wangqian_pumch@126.com

age-standardized DALY rate decreased from 13.21 to 8.24 per 100,000 by -1.52%. Females
exhibited a higher incidence rate but lower mortality and DALY rates. The burden of PAH
distributed unequally, with regions possessing higher socioeconomic statuses exhibiting lower
mortality and DALY rates. Such inequalities have been improved over past decades.

41 Conclusions

42 The decline in mortality and DALY rates of PAH indicates improvements in disease management

43 and patient outcomes, while the health inequalities among different regions and countries persist.

- 44 Improving survival and life quality, and global health equality are crucial for future progress.
- 45

46 Keywords

47 Pulmonary arterial hypertension, Global burden, Mortality, Disability-adjusted life years, Health48 inequality

49

50 Introduction

51 Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by extensive 52 pulmonary vasoconstriction and pulmonary vascular remodeling, and the progressive increased pulmonary vascular resistance eventually leads to right ventricular failure.^{1,2} Despite existing 53 studies on the disease burden of PAH across diverse geographies and etiologies, ³ a comprehensive, 54 55 global investigation remains lacking. Prevailing studies report a mean prevalence ranging from 3 to 5 cases per 100,000 individuals, with incidence rates fluctuating between 0.40 to 0.58 cases per 56 100,000 person-years according to systematic reviews.^{4,5} Such variation is often ascribed to the 57 heterogeneity of included studies and the inconsistent application of diagnostic criteria. With the 58 continuous changes in global demographics, the evolving definitions and classifications of PAH, 59 and dynamic therapeutic landscape, ^{6,7} it is essential to systematically evaluate the contemporary 60 global disease burden. 61

The Global Burden of Disease (GBD) study is the largest worldwide program to quantify health 62 loss across global regions and over time, aiming to improve health outcomes.⁸ The latest GBD 63 database notably includes, for the first time, comprehensive data on the burden of PAH from 1990 64 to 2021.⁹ Such data is instrumental for advancing our understanding of PAH's epidemiological 65 trends. In this study, we used the GBD database to investigate PAH associated prevalence, 66 67 incidence, mortality, and disability adjusted life years (DALYs) at global, regional, and national 68 level from 1990 to 2021, stratified by age, sex, and sociodemographic development. This 69 comprehensive analysis of the global PAH burden is expected to inform future strategies for 70 disease screening, surveillance, and management.

71 Methods

72 Overview and data source

The GBD 2021 study encompassed a comprehensive spectrum of 371 diseases and injuries, along with 88 risk factors, across 204 countries and territories. This study provides an in-depth look at the health metrics including prevalence, incidence, mortality, DALYs, and age-standardized rates (ASRs) by cause, age, sex, year, and location. ^{9,10} For this research, data on the global, regional and national disease burden of PAH from 1990 to 2021 was collected from The Global Health

78 Data Exchange GBD Results Tool (https://vizhub.healthdata.org/gbd-results/).

79 Disease definition

- 80 PAH in this study is limited to only the World Health Organization's (WHO) Group 1 pulmonary
- 81 hypertension.³ The diagnosis of PAH was established through either right heart catheterization or
- 82 echocardiography and was confirmed by physician.

83 Statistical analysis

Numbers, crude rates, ASRs including age-standardized prevalence rates (ASPRs), age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized disability-adjusted life-year rates (ASDRs), and 95% uncertainty interval (95%)

- 87 UI) data were extracted from GBD. ASRs were calculated with the following formula: ASR =
- 88 $\frac{\sum (a_i \times w_i)}{\sum w_i} \times 100,000$, in which *i* denotes the *i*th age group, a_i indicates the age-specific rates in this

group, and w_i represents the population weight for the corresponding age group in the reference

- 90 standard population. DALYs were calculated as the sum of years lived with disability (YLD) and 91 years of life lost (YLL).
- 92 The joinpoint regression model was utilized to examine the linear trends in the disease burden of
- 93 PAH from 1990 to 2021. This model employs the least squares method to minimize potential
- 94 subjectivity in trend estimation. The average annual percent change (AAPC) was calculated to
- 95 quantify significant trends using the following formula: AAPC = $\left\{ exp\left(\frac{\sum(b_i \times \omega_i)}{\sum \omega_i}\right) 1 \right\} \times 100\%$, in
- 96 which *i* denotes the i^{th} desired segment of the time series, b_i indicates the slope coefficient of this 97 segment, and w_i represents the duration of the segment in years. A positive AAPC, with both the 98 estimate and its 95% confidence interval (CI) above zero, indicates an increasing trend, while a

99 negative AAPC, with both values below zero, signifies a decreasing trend for the specific variable.

- 100 The Socio-demographic Index (SDI) serves as a comprehensive measure of a country or region's developmental progress, taking into account a spectrum of socioeconomic factors including 101 income equality, educational levels, and fertility rates among young females.⁹ With a scale 102 103 ranging from 0 to 1, a higher SDI value indicates a more advanced state of socioeconomic 104 development. The correlation between the disease burden of PAH and socioeconomic 105 development in different countries and regions was analyzed to evaluate global health inequalities. 106 The slope index of inequality (SII) was employed to quantify absolute inequalities by measuring 107 the gradient of the regression line between the ASDR of PAH and weighted ranking of each country and territory.¹¹ 108
- All data analysis and visualization were performed using Joinpoint Regression Program (version
 5.1.0.0, Statistical Research and Applications Branch, National Cancer Institute, USA) and the
 open-source software R (version 4.3.2; R Foundation for Statistical Computing, Vienna, Austria).

112 **Role of the funding source**

113 The funders of the study had no role in study design, data collection, data analysis, data 114 interpretation, writing of the report, or decision to submit the paper for publication.

- 115
- 116 Results

117 Global trends

118In 2021, the global prevalence of PAH was 191.81×10^3 cases (95% UI, 155.36×10^3 to119 235.79×10^3), increased by 81.47% compared to which of 1990 (105.7×10^3 , 95% UI 86.38×10^3 to120 130.33×10^3). However, the ASPR of PAH showed a slight decline between 1990 and 2021 from1212.30/100,000 (95% UI 1.87/100,000 to 2.82/100,000) to 2.28/100,000 (95% UI 1.85/100,000 to1222.80/100,000). The ASIR of PAH was 0.50/100,000 (95% UI 0.40/100,000 to 0.60/100,000) in1231990 and increased to 0.52/100,000 (95% UI 0.42/100,000 to 0.62/100,000) in 2021, with an124AAPC of 0.10% (95% CI, 0.10% to 0.11%) (Table 1).

Despite an increase in the number of death cases, the ASMR in 2021 (0.27/100,000, 95% UI 0.23/100,000 to 0.32/100,000) was lower than which in 1990 (0.35/100,000, 95% UI 0.29/100,000) to 0.42/100,000), with an AAPC of -0.82% (95% CI -0.95% to -0.68%) between 1990 and 2021. A similar and more pronounced trend was observed in the ASDR, which decreased from 13.21/100,000 (95% UI 10.78/100,000 to 15.36/100,000) in 1990 to 8.24/100,000 (95% UI 10.78/100,000 to 15.36/100,000) in 1990 to 8.24/100,000 (95% UI 7.14/100,000 to 9.39/100,000) in 2021, with an AAPC of -1.52% (95% CI -1.64% to -1.40%) (Table 1 and Structured Graphical Abstract).

132 Age and sex patterns

133 In both 1990 and 2021, the incidence of PAH was generally higher in females than in males. The 134 ASIR in 2021 was 0.48/100,000 (95% UI 0.39/100,000 to 0.58/100,000) for males and 135 0.55/100,000 (0.45/100,000 to 0.66/100,000) for females. The AAPC in ASIR from 1990 to 2021 136 was 0.08% (95% CI 0.08% to 0.09%) for males and 0.12% (95% CI, 0.11% to 0.14%) for females, indicating rising trends in PAH incidence across both sexes (Table1 and Supplementary Fig 1A). 137 138 In 2021, the highest incident cases and rates were observed in the 55-59 years age group and the 139 75-79 years age group, respectively for both sexes, and the incidence rate increased with age in the 140 population under 75 years. Across all age groups, the incidence rate in females consistently 141 exceeded that in males (Fig 1A).

142 In 2021, females exhibited a higher number of death cases and a greater ASMR compared to 143 males. However, females typically had lower ASMRs in most years, as depicted in Supplementary 144 Fig 1b. The ASMR declined more markedly in males than in females between 1990 and 2021, 145 with an AAPC of -1.04% (95% CI -1.17% to -0.92%) for males and -0.61% (95% CI -0.73% to 146 -0.49%) for females (Table 1). Within the patient population aged 5 to 80 years, both the number of death cases and the mortality rate increased with age for both sexes. Notably, children aged 0 to 147 5 years represented a significant part of death cases, with 1.41×10^3 cases (95% UI 1.08×10³ to 148 1.78×10^3) (Fig 1B). YLL constituted the majority of DALYs for PAH, as shown in Supplementary 149 150 Fig 2. Consistent with mortality trends, females generally presented lower ASDRs than males over 151 the past three decades (Supplementary Fig 1C). Declining trends in ASDRs were observed for 152 both sexes from 1990 to 2021, with a more significant decrease in males, as indicated by an AAPC 153 of -1.80% (95% CI -1.90% to -1.70%) compared to -1.26% (95% CI -1.37% to -1.15%) in females 154 (Table 1). Children under 5 years contributed the most to the total DALY numbers in both sexes, 155 and the DALY rates increased with age in populations over 5 years old (Fig 1C). From 1990 to 156 2021, most age groups showed downward trends in mortality and DALY rates, particularly in 157 those under 5 years, with AAPCs of -3.16% (95% CI -3.37% to -2.94%) for mortality rate and 158 -3.16% (95% CI -3.37% to -2.95%) for DALY rate. However, in individuals over 85 years, both 159 mortality and DALY rates continued to increase from 1990 to 2021 (Table 1).

160 Regional trends

161 Among the 21 regions analyzed, the ASIR of PAH in 2021 varied from 0.30/100,000 (95% UI 162 0.24/100,000 to 0.37/100,000) in High-income North America to 0.92/100,000 (95% UI 163 0.75/100,000 to 1.09/100,000) in Eastern Sub-Saharan Africa (Supplemental Table 2). Generally, 164 regions with higher SDI, such as High-income North America, High-income Asia Pacific, and 165 Australasia exhibited lower incidence rates, while regions with lower socioeconomic development, 166 including Central, Western, and Eastern Sub-Saharan Africa, had higher rates (Fig 2A). Temporal 167 trends in incidence rates differed by region. Central Europe experienced the most rapid increase in 168 ASIR, with an AAPC of 0.60% (95% CI 0.57% to 0.63%), whereas Western Sub-Saharan Africa 169 showed the most significant decline, with an AAPC of -0.84% (95% CI -0.90% to -0.79%) 170 (Supplemental Table 2). In most regions, the incidence rates over the past three decades showed 171 moderate fluctuations (Fig 2A).

172 In 2021, the highest ASMR and ASDR for PAH were observed in North Africa and Middle East, 173 at 0.44/100,000 (95% UI 0.31/100,000 to 0.53/100,000) and 14.81/100,000 (95% UI 174 10.76/100,000 to 17.96/100,000), respectively. In contrast, Central Latin America reported the 175 lowest rates, with an ASMR of 0.08/100,000 (95% UI 0.07/100,000 to 0.10/100,000) and an 176 ASDR of 3.00/100,000 (95% UI 2.63/100,000 to 3.51/100,000) (Supplemental Table 3 and 177 Supplemental Table 4). Between 1990 and 2021, all regions except Central Asia, which showed a 178 non-significant trend, experienced significant declines in both ASMR and ASDR. The most 179 significant decreases were noted in Eastern Europe, with an AAPC of ASMR at -2.98% (95% CI 180 -3.74% to -2.21%) and an AAPC of ASDR at -3.22% (95% CI, -4.10% to -2.34%) (Supplemental 181 Table 3 and Supplemental Table 4). In most regions, there was a general trend of decreasing 182 age-standardized mortality and DALY rates with increasing SDI, although some regions exhibited 183 considerable variations (Fig 2B and Fig 2C).

184 National trends

185 In 2021, the ASIRs of PAH varied significantly across countries and territories, ranging from 0.18 186 to 1.06 per 100,000 persons. Zambia reported the highest ASIR at 1.06/100,000 (95% UI 187 0.88/100,000 to 1.28/100,000), followed by Uganda (1.00/100,000, 95% UI 0.82/100,000 to 188 1.20/100,000), and Ethiopia (1.00/100,000, 95% UI 0.82/100,000 to 1.19/100,000). In contrast, 189 the lowest rates were observed in Ireland (0.18/100,000, 95% UI 0.15/100,000 to 0.23/100,000), 190 Canada (0.26/100,000, 95% UI 0.21/100,000 to 0.32/100,000), and Portugal (0.28/100,000, 95% 191 UI 0.23/100,000 to 0.34/100,000) (Supplemental Table 2 and Supplemental Fig 3A). From 1990 to 192 2021, about half of the countries and territories experienced an increase in age-standardized 193 incidence rates (Supplemental Fig 4A). Slovakia experienced the most substantial increase (AAPC 194 1.07%, 95% CI 0.95% to 1.19%), while Senegal showed the greatest decrease (AAPC -1.61%, 95% 195 CI -1.70% to -1.52%). Among 204 countries and territories, an inverse correlation was observed 196 between the SDI and the incidence rate, aligning with the patterns seen in regional trends 197 (Supplemental Fig 5A). 198 The age-standardized rate of mortality and DALYs also varied in distinct countries and territories.

In 2021, the highest burden of disease was observed in Mongolia and Georgia, with ASMRs of 1.59/100,000 (95% UI 0.91/100,000 to 2.05/100,000) and 1.01/100,000 (95% UI 0.79/100,000 to 1.27/100,000), respectively, and ASDRs of 43.92/100,000 (95% UI 25.60/100,000 to 56.54/100,000) and 27.83/100,000 (95% UI 22.18/100,000 to 34.82/100,000), respectively. The

Republic of Moldova reported the lowest ASMR at 0.01/100,000 (95% UI 0.01/100,000 to 0.01/100,000) and ASDR at 0.54/100,000 (95% UI 0.44/100,000 to 0.68/100,000), followed by Montenegro and Slovenia, which also had notably low rates (Fig 3A, Supplemental Fig 3B, Supplemental Table 3 and Supplemental Table 4). Between 1990 and 2021, approximately 90% of countries and territories demonstrated a decline in both ASMRs and ASDRs, while few of them showed upward trends, such as Latvia and Mauritius (Fig 3B and Supplemental Fig 4B). In 2021, a statistically significant negative correlation between increasing SDI and both mortality and

210 DALY rates was observed at the national level (Supplemental Fig 5B-C).

211 Health Inequalities

Overall, regions with lower SDI exhibited higher age-standardized incidence and DALY rates for PAH, while regions with higher socioeconomic status showed the opposite trend (Table 1). Regarding health disparities, the SII of ASDR in 1990 was -4.07 per 100,000 (95% CI -6.19 to -1.95), indicating an inverse relationship between PAH disease burden and socioeconomic development. By 2021, the SII had reduced to -3.55 per 100,000 (95% CI -4.87 to -2.23). The convergence of the SII towards zero between 1990 and 2021 indicates a more equitable global distribution of PAH burden.

219

220 Discussion

Despite the advent of novel drugs and treatment strategies, PAH remains a life-threatening disease imposing a significant burden in the modern era. Accurate epidemiological data is challenging to obtain due to evolving diagnostic criteria and the subtle early symptoms of the disease. This study, utilizing the GBD 2021 data, provides the first comprehensive summary and analysis of the global PAH burden over the past three decades. It offers valuable insights into disease patterns, aiming to inform enhanced diagnosis and management strategies for the future.

227 The overall prevalence and incidence rates of PAH observed in this study are consistent with data from other registries, ¹²⁻¹⁵ and have remained relatively stable over the past three decades. 228 According to GBD 2021, both age-standardized prevalence and incidence rate of PAH were higher 229 in females than in males, which is also observed across many other cohorts. ¹⁶⁻¹⁸ The higher 230 incidence of PAH in females may be attributed to distinctions in estrogen metabolism, function, 231 and receptor expression, ¹⁹ as well as autoimmune factors and variable penetrance of gene 232 mutations in specific PAH subtypes.^{20,21} In this study, females have generally exhibited lower 233 age-standardized mortality and DALY rates compared to males, and better survival in females was 234 also observed in previous clinical trials.²² This survival advantage may be due to superior right 235 ventricular contractility and adaptation and better response to treatment in females, potentially 236 enhanced by the protective effects of estrogen during the disease process. ^{19,23} 237

Our study observed a shift in the median age of PAH diagnosis from 45-49 years in 1990 to 50-54 years by 2021, a trend consistent with previous reports. ^{12,16,17,24} This demographic shift underscores the growing need of focusing on elderly patients, who frequently present with increased cardiovascular comorbidities and higher mortality rate, and face challenges in receiving an early and accurate diagnosis. ²⁵ Another age group that calls for emphasis is children under the age of 5. Pediatric PAH, predominantly idiopathic PAH and PAH associated with congenital heart disease, is particularly challenging due to the delayed diagnosis often resulting from the inability

of young children to report their symptoms effectively.²⁶ Despite a decline from 1990 to 2021, the
DALY burden remains significantly high in this age group, highlighting the need for improved
pediatric PAH management. Future efforts should focus on non-invasive diagnostic methods,
support for maintaining normal daily activities, and strategies aimed at prolonging survival.²⁷

249 Over the past three decades, there has been a gradual decline in the global disease burden of PAH, 250 as measured by mortality and DALYs. The predominant component of DALYs is YLL, indicating 251 that the reduction in life expectancy due to PAH accounts for the most significant portion of its 252 disease burden. Therefore, improving patient survival is of great importance. Although increased 253 disease awareness and early diagnosis also contribute to improved survival in PAH, the marked 254 reduction in mortality and DALYs is likely primarily due to the advent of targeted therapies. 255 Previous studies have demonstrated significant improvements in the 1-, 3-, and 5-year survival of PAH patients since the introduction of these therapies. ^{17,18,28,29} With the continuous update of 256 high-level clinical evidence, combination therapy with targeted drugs has become the first-line 257 recommendation in international guidelines for most of the PAH patients.³⁰⁻³³ Moreover, beyond 258 259 the traditional pathways of prostacyclin, endothelin and nitric oxide, a variety of novel therapeutic 260 targets are emerging, with candidates such as sotatercept—a fusion protein inhibiting activin receptor type IIA signaling-and imatinib-a tyrosine kinase inhibitor-currently under clinical 261 investigation.² For future advancements, the relatively high mortality rate in PAH necessitates 262 263 further transformative innovations, and enhancing the quality of life for patients remains a critical 264 issue.

265 Despite the overall decline in PAH mortality and DALYs, the disease burden remains unevenly 266 distributed across regions and nations. Some previous researches have described health disparities in PAH diagnosis and treatment, influenced by socioeconomic status, race, and ethnicity in certain 267 countries.³⁴ While the environmental and genetic factors associated with geographic variations in 268 PAH incidence are not fully understood, differences in etiological distributions may contribute to 269 270 the observed disparities. In Africa, PAH prevalence is often linked to HIV infection, whereas in South America, schistosomiasis is a significant cause, with these infectious diseases being more 271 prevalent in low- and middle-income countries.³⁵ The global distribution of mortality and DALYs 272 273 is of even greater concern, with the GBD 2021 indicating a general correlation between lower SDI 274 and higher age-standardized mortality and DALY rates. One significant reason is the delayed 275 diagnosis and treatments in underdeveloped regions, resulting in more advanced disease stages at diagnosis and poorer survival outcomes.³⁶ Lower socioeconomic status has been identified as an 276 independent risk factor for disease progression and mortality in idiopathic PAH.³⁷ In contrast, in 277 more developed regions, both underlying diseases and PAH are more likely to receive specialized 278 279 care. Additionally, the limited availability and high cost of targeted therapies may result in 280 suboptimal treatment in low SDI countries. Therefore, the development of region- or country-specific guidelines and consensus will be instrumental in advancing the specialized 281 management of PAH patients. ³⁸ The analysis of health disparities reveals a promising trend 282 283 towards a more equitable global distribution of PAH burden in 2021 compared to 1990, 284 underscoring the need for continued focus on this issue in clinical practice and research moving 285 forward.

This study also has some limitations. Firstly, the majority of data in GBD database are secondary data collected from other research organizations, which may potentially lead to the

underestimation of the disease burden. The further modeling and estimation process may introduce a degree of uncertainty. Secondly, the diagnostic criteria and classification systems for PAH have evolved over the years, and the difference between diagnostic methods of right heart catheterization and echocardiography also contribute to the heterogeneity. Finally, due to constraints in the available data, this study was unable to assess the disease burden associated with each subtype of PAH, and a comprehensive investigation of potential risk factors for PAH remains a task for future research.

In conclusion, this study presents the first systematic assessment of the global, regional, and national disease burden of PAH spanning the past three decades. The advancements in early diagnosis and targeted therapies have led to a significant decline in the mortality and DALYs. However, disparities in PAH burden persist across regions and countries, with health inequalities being closely linked to socioeconomic disparities. Enhancing survival, improving the quality of life, and promoting equitable access to PAH diagnosis and treatment are crucial for future progress in the field.

302

303 Data availability

The data used for analysis are publicly available from The Global Health Data Exchange GBD
 Results Tool (https://vizhub.healthdata.org/gbd-results/).

306 Author contributions

307 YD and QW conceived and designed the study. YD, XD, and JQ conducted the literature review.

YD conducted data analysis and visualization. YD, YW, and QW drafted the original manuscript.
 ML, XZ, and QW contributed to the funding acquisition. All authors contributed to the

310 interpretation of findings and critical revision of the article. All authors had approved the final 311 version and accepted responsibility to submit for publication.

312 **Conflict of interest**

313 The authors declare that they have no competing interests.

314 Acknowledgements

The authors would like to thank the GBD 2021 and its collaborators for providing the publicly available data.

317 Funding

This study was supported by the Chinese National Key Technology R&D Program, Ministry of
Science and Technology (2021YFC2501301-5); CAMS Innovation Fund for Medical Sciences
(CIFMS) (2021-I2M-1-005, 2019-I2M-2-008); and National High Level Hospital Clinical
Research Funding (2022-PUMCH-D-009).

322

323 References

Naeije R, Richter MJ, Rubin LJ. The physiological basis of pulmonary arterial hypertension. *Eur Respir J* 2022;59. doi: 10.1183/13993003.02334-2021

- 326 2. Ghofrani HA, Gomberg-Maitland M, Zhao L, Grimminger F. Mechanisms and treatment of
- 327 pulmonary arterial hypertension. *Nat Rev Cardiol* 2024. doi: 10.1038/s41569-024-01064-4
- 328 3. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical

classification of pulmonary hypertension. *Eur Respir J* 2019;**53**. doi: 10.1183/13993003.01913-2018

330 4. Emmons-Bell S, Johnson C, Boon-Dooley A, et al. Prevalence, incidence, and survival of

pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. *Pulm*

332 *Circ* 2022;**12**:e12020. doi: 10.1002/pul2.12020

5. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension: identification of the most accurate estimates from a
systematic literature review. *Pulm Circ* 2021;11:2045894020977300. doi: 10.1177/2045894020977300

- Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. *Jama* 2022;**327**:1379-1391. doi: 10.1001/jama.2022.4402
- 338 7. Weatherald J, Boucly A, Peters A, *et al.* The evolving landscape of pulmonary arterial
 339 hypertension clinical trials. *Lancet* 2022;**400**:1884-1898. doi: 10.1016/s0140-6736(22)01601-4
- 8. Network. GBoDC. Global Burden of Disease Study 2021 (GBD 2021) Results. In. Seattle, United
 States: Institute for Health Metrics and Evaluation (IHME). 2022.

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years
(DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and
territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of
Disease Study 2021. *Lancet* 2024;403:2133-2161. doi: 10.1016/s0140-6736(24)00757-8

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational
locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*2024;403:2162-2203. doi: 10.1016/s0140-6736(24)00933-4

349 11. Organization WH. Handbook on health inequality monitoring with a special focus on low- and
 350 middle-income countries: Handbook on health inequality monitoring with a special focus on low- and
 351 middle-income countries.; 2013.

12. Ling Y, Johnson MK, Kiely DG, *et al.* Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. *Am J Respir Crit Care Med* 2012;**186**:790-796. doi:

355 10.1164/rccm.201203-0383OC

356 13. Wijeratne DT, Lajkosz K, Brogly SB, et al. Increasing Incidence and Prevalence of World Health

357 Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario,

358 Canada. Circ Cardiovasc Qual Outcomes 2018;11:e003973. doi: 10.1161/circoutcomes.117.003973

359 14. Strange G, Playford D, Stewart S, *et al.* Pulmonary hypertension: prevalence and mortality in the

360 Armadale echocardiography cohort. *Heart* 2012;**98**:1805-1811. doi: 10.1136/heartjnl-2012-301992

15. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of
 pulmonary arterial hypertension. *Eur Respir J* 2007;**30**:104-109. doi: 10.1183/09031936.00092306

Humbert M, Sitbon O, Chaouat A, *et al.* Pulmonary arterial hypertension in France: results from a
national registry. *Am J Respir Crit Care Med* 2006;**173**:1023-1030. doi: 10.1164/rccm.200510-16680C

365 17. Benza RL, Miller DP, Barst RJ, *et al.* An evaluation of long-term survival from time of diagnosis

in pulmonary arterial hypertension from the REVEAL Registry. *Chest* 2012;142:448-456. doi:
10.1378/chest.11-1460

368 18. D'Alonzo GE, Barst RJ, Ayres SM, *et al.* Survival in patients with primary pulmonary
369 hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;115:343-349. doi:
370 10.7326/0003-4819-115-5-343

371 19. Cheron C, McBride SA, Antigny F, *et al.* Sex and gender in pulmonary arterial hypertension. *Eur*372 *Respir Rev* 2021;30. doi: 10.1183/16000617.0330-2020

20. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of

- genetic anticipation in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med*2012;**186**:892-896. doi: 10.1164/rccm.201205-0886OC
- 376 21. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated
- 377 pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
- 378 *Chest* 2010;**138**:1383-1394. doi: 10.1378/chest.10-0260
- 379 22. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and
- anorexigen-associated pulmonary arterial hypertension in the modern management era. *Circulation* 2010;122:156-163. doi: 10.1161/circulationaha.109.911818
- 382 23. Dignam JP, Sharma S, Stasinopoulos I, MacLean MR. Pulmonary arterial hypertension: Sex
 383 matters. *Br J Pharmacol* 2024;**181**:938-966. doi: 10.1111/bph.16277
- 24. Ventetuolo CE, Moutchia J, Baird GL, *et al.* Baseline Sex Differences in Pulmonary Arterial
 Hypertension Randomized Clinical Trials. *Ann Am Thorac Soc* 2023;20:58-66. doi:
 10.1513/AnnalsATS.202203-207OC
- 387 25. Hjalmarsson C, Rådegran G, Kylhammar D, *et al.* Impact of age and comorbidity on risk
 388 stratification in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2018;**51**. doi:
 389 10.1183/13993003.02310-2017
- 390 26. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension:
- insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease
 management. *Circulation* 2012;**125**:113-122. doi: 10.1161/circulationaha.111.026591
- Humbert M, Kovacs G, Hoeper MM, *et al.* 2022 ESC/ERS Guidelines for the diagnosis and
 treatment of pulmonary hypertension. *Eur Heart J* 2022;43:3618-3731. doi: 10.1093/eurheartj/ehac237
- 395 28. Jing ZC, Xu XO, Han ZY, *et al.* Registry and survival study in chinese patients with idiopathic
- and familial pulmonary arterial hypertension. *Chest* 2007;**132**:373-379. doi: 10.1378/chest.06-2913
- 397 29. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial
- hypertension in the modern treatment era. *Chest* 2011;**140**:301-309. doi: 10.1378/chest.10-2327
- 30. Humbert M, Kovacs G, Hoeper MM, *et al.* 2022 ESC/ERS Guidelines for the diagnosis and 400 treatment of pulmonary hypertension. *Eur Respir J* 2023;**61**. doi: 10.1183/13993003.00879-2022
- 401 31. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and
- 402 treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of
- 403 Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory
- 404 Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC),
- International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2016;37:67-119. doi:
 10.1093/eurheartj/ehv317
- 407 32. Galiè N, Hoeper MM, Humbert M, *et al.* Guidelines for the diagnosis and treatment of pulmonary 408 hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the 409 European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the
- 410 International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2009;**30**:2493-2537. doi:
- 411 10.1093/eurheartj/ehp297
- 412 33. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial
- 413 hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the
- 414 European Society of Cardiology. Eur Heart J 2004;25:2243-2278. doi: 10.1016/j.ehj.2004.09.014
- 415 34. Talwar A, Morel KC, Perez VD, Talwar A. The Impact of Socioeconomic, Racial, and Ethnic
- 416 Disparities on Pulmonary Hypertension Diagnosis and Treatment. Advances in Pulmonary

- 417 Hypertension 2022. doi:
- 418 35. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet
- 419 Respir Med 2016;4:306-322. doi: 10.1016/s2213-2600(15)00543-3
- 420 36. Talwar A, Sahni S, Talwar A, Kohn N, Klinger JR. Socioeconomic status affects pulmonary
- 421 hypertension disease severity at time of first evaluation. *Pulm Circ* 2016;6:191-195. doi:
 422 10.1086/686489
- 423 37. Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes
- 424 in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;187:303-310. doi:
 425 10.1164/rccm.201207-12900C
- 426 38. Zhao J, Wang Q, Wang Q, et al. 2020 Chinese Expert-based Consensus on the Diagnosis and
- 427 Treatment of Connective Tissue Disease Associated Pulmonary Arterial Hypertension. Rheumatol
- 428 Immunol Res 2021;2:63-78. doi: 10.2478/rir-2021-0010

	Incidence (95% UI)			Deaths (95% UI)			DALYs (95% UI)		
	Incident cases in 2021 (000s)	ASIR in 2021 (per 100,000)	AAPC of ASIR (95% CI)	Death cases in 2021 (000s)	ASMR in 2021 (per 100,000)	AAPC of ASMR (95% CI)	DALY cases in 2021 (000s)	ASDR in 2021 (per 100,000)	AAPC of ASDR (95% CI)
Global	43.25 (34.7 to 52.44)	0.52 (0.42 to 0.62)	0.10 (0.10 to 0.11)	22.02 (18.24 to 25.35)	0.27 (0.23 to 0.32)	-0.82 (-0.95 to -0.68)	642.1 (552.27 to 728.99)	8.24 (7.14 to 9.39)	-1.52 (-1.64 to -1.40)
Sex									
Female	23.42 (18.89 to 28.35)	0.55 (0.45 to 0.66)	0.12 (0.11 to 0.14)	12.44 (10 to 15.38)	0.28 (0.22 to 0.34)	-0.61 (-0.73 to -0.49)	342.47 (282.65 to 430.64)	8.39 (6.92 to 10.53)	-1.26 (-1.37 to -1.15)
Male	19.83 (15.82 to 24.09)	0.48 (0.39 to 0.58)	0.08 (0.08 to 0.09)	9.58 (7.52 to 11.7)	0.27 (0.21 to 0.33)	-1.04 (-1.17 to -0.92)	299.64 (246.73 to 348.33)	8.06 (6.72 to 9.36)	-1.80 (-1.90 to -1.70)
SDI levels									
High SDI	5.61 (4.5 to 6.96)	0.37 (0.29 to 0.44)	-0.02 (-0.03 to -0.01)	4.62 (3.92 to 5.05)	0.22 (0.19 to 0.23)	-0.59 (-0.75 to -0.44)	93.18 (84.87 to 99.19)	6.16 (5.76 to 6.49)	-1.29 (-1.45 to -1.14)
High-middle SDI	7.73 (6.19 to 9.59)	0.46 (0.37 to 0.55)	0.19 (0.17 to 0.21)	4.33 (3.59 to 5.14)	0.24 (0.2 to 0.29)	-1.22 (-1.50 to -0.95)	99.45 (85.76 to 117.64)	6.48 (5.61 to 7.87)	-2.27 (-2.48 to -2.07)
Middle SDI	14.17 (11.32 to 17.38)	0.53 (0.43 to 0.64)	-0.02 (-0.03 to -0.01)	7.55 (5.14 to 9.03)	0.33 (0.22 to 0.39)	-1.06 (-1.19 to -0.93)	197.17 (148.78 to 232.32)	8.23 (6.26 to 9.7)	-1.78 (-1.92 to -1.64)
Low-middle SDI	9.98 (8.09 to 12.02)	0.59 (0.47 to 0.7)	-0.07 (-0.10 to -0.03)	3.73 (2.76 to 5.09)	0.26 (0.18 to 0.38)	-0.89 (-1.03 to -0.75)	156.4 (122.43 to 194.17)	9.07 (7.05 to 11.6)	-1.59 (-1.70 to -1.47)
Low SDI	5.71 (4.68 to 6.85)	0.71 (0.58 to 0.85)	-0.30 (-0.33 to -0.27)	1.78 (1.15 to 2.54)	0.27 (0.15 to 0.40)	-0.53 (-0.81 to -0.25)	95.34 (67.47 to 133.05)	9.3 (6.08 to 13.2)	-0.92 (-1.04 to -0.80)
Age	Incident cases in 2021 (000s)	Incidence rate in 2021 (per 100,000)	AAPC of ASIR (95% CI)	Death cases in 2021 (000s)	Mortality rate in 2021 (per 100,000)	AAPC of ASMR (95% CI)	DALY cases in 2021 (000s)	DALY rate in 2021 (per 100,000)	AAPC of ASDR (95% CI)
<5 years	1.20 (0.89 to 1.63)	0.18 (0.14 to 0.25)	0.11 (0.10 to 0.12)	1.41 (1.08 to 1.78)	0.21 (0.16 to 0.27)	-3.16 (-3.37 to -2.94)	125.96 (96.51 to 159.4)	19.14 (14.66 to 24.22)	-3.16 (-3.37 to -2.95)
5-9 years	1.26 (0.91 to 1.68)	0.18 (0.13 to 0.24)	0.11 (0.10 to 0.12)	0.15 (0.12 to 0.19)	0.02 (0.02 to 0.03)	-2.07 (-2.31 to -1.84)	12.81 (10.35 to 15.87)	1.86 (1.51 to 2.31)	-2.04 (-2.27 to -1.81)

429 Table 1. Global incidence, deaths, and DALYs and their annual trends of pulmonary arterial

Age	Incident cases in 2021 (000s)	Incidence rate in 2021 (per 100,000)	AAPC of ASIR (95% CI)	Death cases in 2021 (000s)	Mortality rate in 2021 (per 100,000)	AAPC of ASMR (95% CI)	DALY cases in 2021 (000s)	DALY rate in 2021 (per 100,000)	AAPC of ASDR (95% CI
10-14 years	1.24 (0.74 to 1.93)	0.19 (0.11 to 0.29)	0.14 (0.13 to 0.15)	0.15 (0.12 to 0.19)	0.02 (0.02 to 0.03)	-1.34 (-1.58 to -1.10)	12.33 (9.82 to 15.35)	1.85 (1.47 to 2.3)	-1.31 (-1.54 to -1.07)
15-19 years	1.34 (0.87 to 2.04)	0.21 (0.14 to 0.33)	0.21 (0.17 to 0.24)	0.26 (0.21 to 0.33)	0.04 (0.03 to 0.05)	-1.04 (-1.18 to -0.91)	19.27 (15.49 to 24.75)	3.09 (2.48 to 3.97)	-1.02 (-1.15 to -0.88)
20-24 years	1.59 (1.03 to 2.35)	0.27 (0.17 to 0.39)	0.21 (0.19 to 0.23)	0.33 (0.26 to 0.42)	0.05 (0.04 to 0.07)	-0.76 (-0.82 to -0.71)	22.87 (18.25 to 28.91)	3.83 (3.06 to 4.84)	-0.71 (-0.80 to -0.61)
25-29 years	1.85 (1.03 to 2.86)	0.31 (0.18 to 0.49)	0.19 (0.18 to 0.20)	0.42 (0.35 to 0.51)	0.07 (0.06 to 0.09)	-0.90 (-0.98 to -0.82)	27.21 (22.50 to 32.56)	4.62 (3.82 to 5.53)	-0.88 (-0.95 to -0.80)
30-34 years	2.32 (1.48 to 3.42)	0.38 (0.25 to 0.57)	0.15 (0.13 to 0.17)	0.4 (0.34 to 0.48)	0.07 (0.06 to 0.08)	-1.03 (-1.21 to -0.85)	24.18 (20.20 to 28.86)	4.00 (3.34 to 4.77)	-0.99 (-1.16 to -0.81)
35-39 years	2.69 (1.79 to 3.89)	0.48 (0.32 to 0.69)	0.14 (0.13 to 0.16)	0.48 (0.41 to 0.56)	0.09 (0.07 to 0.10)	-1.14 (-1.28 to -0.99)	26.53 (22.78 to 30.79)	4.73 (4.06 to 5.49)	-1.09 (-1.23 to -0.95)
40-44 years	2.87 (1.59 to 4.57)	0.57 (0.32 to 0.91)	0.15 (0.13 to 0.17)	0.62 (0.52 to 0.73)	0.12 (0.10 to 0.15)	-1.17 (-1.37 to -0.97)	30.89 (26.22 to 35.88)	6.17 (5.24 to 7.17)	-1.13 (-1.32 to -0.94)
45-49 years	3.33 (2.07 to 4.91)	0.70 (0.44 to 1.04)	0.08 (0.07 to 0.09)	0.52 (0.45 to 0.62)	0.11 (0.09 to 0.13)	-1.26 (-1.41 to -1.10)	23.74 (20.37 to 27.85)	5.01 (4.30 to 5.88)	-1.20 (-1.34 to -1.05)
50-54 years	3.86 (2.57 to 5.59)	0.87 (0.58 to 1.26)	0.08 (0.07 to 0.09)	0.74 (0.62 to 0.86)	0.17 (0.14 to 0.19)	-1.40 (-1.57 to -1.23)	29.66 (25.33 to 34.27)	6.67 (5.69 to 7.70)	-1.34 (-1.52 to -1.15)
55-59 years	4.08 (2.43 to 6.40)	1.03 (0.61 to 1.62)	0.05 (0.02 to 0.08)	1.10 (0.86 to 1.32)	0.28 (0.22 to 0.33)	-1.13 (-1.30 to -0.97)	38.59 (30.61 to 46.13)	9.75 (7.74 to 11.66)	-1.08 (-1.24 to -0.92)
60-64 years	3.89 (2.56 to 5.67)	1.22 (0.80 to 1.77)	0.07 (0.05 to 0.09)	1.15 (0.91 to 1.34)	0.36 (0.28 to 0.42)	-1.17 (-1.31 to -1.04)	34.71 (27.82 to 39.95)	10.85 (8.69 to 12.48)	-1.13 (-1.26 to -1.01)
65-69 years	3.94 (2.85 to 5.29)	1.43 (1.03 to 1.92)	0.07 (0.05 to 0.09)	1.75 (1.38 to 2.08)	0.63 (0.50 to 0.75)	-0.95 (-1.08 to -0.81)	44.13 (34.81 to 52.09)	16.00 (12.62 to 18.88)	-0.92 (-1.03 to -0.81)
70-74 years	3.32 (2.19 to 4.84)	1.61 (1.06 to 2.35)	0.03 (-0.01 to 0.07)	2.23 (1.69 to 2.66)	1.08 (0.82 to 1.29)	-0.75 (-0.89 to -0.61)	46.04 (34.97 to 54.86)	22.37 (16.99 to 26.65)	-0.73 (-0.86 to -0.60)

Age	Incident cases in 2021 (000s)	Incidence rate in 2021 (per 100,000)	AAPC of ASIR (95% CI)	Death cases in 2021 (000s)	Mortality rate in 2021 (per 100,000)	AAPC of ASMR (95% CI)	DALY cases in 2021 (000s)	DALY rate in 2021 (per 100,000)	AAPC of ASDR (95% CI)
75-79 years	2.19 (1.43 to 3.15)	1.66 (1.09 to 2.39)	0.12 (0.10 to 0.13)	2.55 (1.88 to 3.07)	1.93 (1.43 to 2.33)	-0.46 (-0.78 to -0.14)	41.58 (31.08 to 49.95)	31.53 (23.57 to 37.88)	-0.47 (-0.76 to -0.18)
80-84 years	1.34 (0.95 to 1.82)	1.53 (1.09 to 2.08)	0.09 (0.07 to 0.11)	2.79 (2.07 to 3.39)	3.19 (2.36 to 3.87)	-0.15 (-0.38 to 0.09)	35.42 (26.37 to 42.82)	40.44 (30.11 to 48.89)	-0.13 (-0.35 to 0.08)
85-89 years	0.63 (0.39 to 0.99)	1.38 (0.86 to 2.18)	0.07 (0.05 to 0.10)	2.62 (2.03 to 3.07)	5.72 (4.43 to 6.72)	0.28 (0.10 to 0.47)	26.17 (20.30 to 30.62)	57.24 (44.39 to 66.97)	0.26 (0.08 to 0.45)
90-94 years	0.24 (0.14 to 0.38)	1.34 (0.76 to 2.15)	0.09 (0.07 to 0.10)	1.63 (1.27 to 1.92)	9.13 (7.10 to 10.74)	0.60 (0.40 to 0.80)	14.18 (11.02 to 16.65)	79.27 (61.63 to 93.09)	0.60 (0.40 to 0.79)
95+ years	0.08 (0.04 to 0.14)	1.39 (0.67 to 2.64)	0.06 (0.03 to 0.10)	0.72 (0.52 to 0.85)	13.19 (9.51 to 15.60)	0.91 (0.78 to 1.05)	5.82 (4.20 to 6.87)	106.77 (77.07 to 126.03)	0.88 (0.75 to 1.01)

432 DALYs, disability-adjusted life-years; ASIR, age-standardized incidence rate; ASMR,
 433 age-standardized mortality rate; ASDR, age-standardized disability-adjusted life-year rate; AAPC,

434 average annual percentage change; UI, uncertainty interval; CI, confidence interval.


455


456 Figure legends


- Figure 1. Global numbers and rates of incidence, deaths and DALYs of PAH by age and sex
 in 2021. The dotted lines indicate 95% upper and lower uncertainty intervals. DALY,
 disability-adjusted life-year. (A) The numbers and rates of incidence. (B) The numbers and rates of
 deaths. (C) The numbers and rates of DALYs.
- 461 Figure 2. Age-standardized rates of PAH in global and 21 GBD regions by SDI from 1990 to
- 462 **2021.** 32 continuous points plotted for each GBD region represent the age-standardized rates from
- 463 1990 to 2021 for that region. (A) Disease burden of ASIRs. (B) Disease burden of ASMRs. (C)
- 464 Disease burden of ASDRs. GBD, Global Burden of Disease; SDI, Socio-Demographic Index;
- ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate; ASDR,
 age-standardized disability-adjusted life-year rate.
- 467 Figure 3. Age-standardized DALY rates and the annual trends of PAH in 204 countries and
- 468 **territories.** (A) Disease burden of ASDRs in 2021. (B) The average annual percent changes of ASDRs between 1990 and 2021.
- 470 Figure 4. The inequality of PAH disease burden worldwide in 1990 and 2021. Absolute
- 471 inequality of disease burden was evaluated by SII analysis.
- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480

Α

medRxiv preprint doi: https://poi.org/10.1101/2024.10.25.24316118; this version posted October 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International ficense.







Location

- Global
- △ High-income Asia Pacific
- High-income North America
- × Western Europe
- ▽ Andean Latin America
- Tropical Latin America
- * Central Latin America
- Garibbean
- ☆ Central Europe
- Eastern Europe
- Central Asia
- North Africa and Middle East
- South Asia
- Southeast Asia
- East Asia
- Oceania
- Western Sub-Saharan Africa
- Eastern Sub-Saharan Africa
- Central Sub-Saharan Africa
- Southern Sub-Saharan Africa

Year

- 1990
- 1995 2000
- 2000
 2005
- 2010
- 2015
- 2020

